| A multicenter evaluation of tests for diagnosis of histoplasmosis CA Hage, JA Ribes, NL Wengenack, LM Baddour, M Assi, DS McKinsey, ... Clinical Infectious Diseases 53 (5), 448-454, 2011 | 397 | 2011 |
| Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma D Alapat, J Coviello-Malle, R Owens, P Qu, B Barlogie, JD Shaughnessy, ... American journal of clinical pathology 137 (1), 93-100, 2012 | 162 | 2012 |
| A role for semaphorin 3A signaling in the degeneration of hippocampal neurons during Alzheimer's disease PF Good, D Alapat, A Hsu, C Chu, D Perl, X Wen, DE Burstein, DS Kohtz Journal of neurochemistry 91 (3), 716-736, 2004 | 158 | 2004 |
| Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma L Rasche, D Alapat, M Kumar, G Gershner, J McDonald, CP Wardell, ... Leukemia 33 (7), 1713-1722, 2019 | 137 | 2019 |
| The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma S Thanendrarajan, E Tian, P Qu, P Mathur, C Schinke, F van Rhee, ... Haematologica 102 (9), e364, 2017 | 80 | 2017 |
| Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years V Kaur, A Swami, D Alapat, AO Abdallah, P Motwani, LF Hutchins, ... Hematology 23 (1), 17-24, 2018 | 62 | 2018 |
| Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials SA Danziger, M McConnell, J Gockley, MH Young, A Rosenthal, ... PLoS Medicine 17 (11), e1003323, 2020 | 43 | 2020 |
| Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease CS Nabel, S Sameroff, D Shilling, D Alapat, JR Ruth, M Kawano, Y Sato, ... PLoS One 14 (6), e0218660, 2019 | 38 | 2019 |
| Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma DV Alapat, KB Ain, DA Sloan, KG Monaghan, RG Karabakhtsian Endocrine 39, 148-152, 2011 | 34 | 2011 |
| Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma Y Jethava, A Mitchell, M Zangari, S Waheed, C Schinke, ... Blood cancer journal 6 (7), e453-e453, 2016 | 32 | 2016 |
| Ectopic expression of murine diphosphoinositol polyphosphate phosphohydrolase 1 attenuates signaling through the ERK1/2 pathway C Chu, D Alapat, X Wen, K Timo, D Burstein, M Lisanti, S Shears, ... Cellular signalling 16 (9), 1045-1059, 2004 | 31 | 2004 |
| Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level C Schinke, AM Poos, M Bauer, L John, S Johnson, S Deshpande, ... Blood Advances 6 (22), 5873-5883, 2022 | 28 | 2022 |
| The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype C Schinke, A Hoering, H Wang, V Carlton, S Thanandrarajan, ... Haematologica 102 (8), e313, 2017 | 28 | 2017 |
| Cutaneous manifestations of multiple myeloma and other plasma cell proliferative disorders M Bhutani, Z Shahid, A Schnebelen, D Alapat, SZ Usmani Seminars in Oncology 43 (3), 395-400, 2016 | 28 | 2016 |
| Prolonged prothrombin time correlates with serum monoclonal protein concentration in patients with plasma cell dyscrasia S Pandey, SR Post, DV Alapat, KJ Smock, GR Post International Journal of Laboratory Hematology 35 (4), 421-427, 2013 | 21 | 2013 |
| Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma M Mohan, S Kendrick, A Szabo, N Yarlagadda, D Atwal, Y Pandey, A Roy, ... Blood Advances 6 (3), 808-817, 2022 | 20 | 2022 |
| Fiber-types of sarcomeric proteins expressed in cultured myogenic cells are modulated by the dose of myogenin activity DV Alapat, T Chaudhry, R Ardakany-Taghavi, DS Kohtz Cellular signalling 21 (1), 128-135, 2009 | 18 | 2009 |
| Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias A Sridharan, CD Schinke, G Georgiev, M Da Silva Ferreira, ... Blood advances 3 (23), 3962-3967, 2019 | 15 | 2019 |
| Biphenotypic plasma cell myeloma: two cases of plasma cell neoplasm with a coexpression of kappa and lambda light chains S Jiwani, J Bornhost, D Alapat International Journal of Clinical and Experimental Pathology 8 (7), 8536, 2015 | 14 | 2015 |
| Preemptive intravenous immunoglobulin allows safe and timely administration of antineoplastic therapies in patients with multiple myeloma and parvovirus B19 disease L Katragadda, Z Shahid, A Restrepo, J Muzaffar, D Alapat, E Anaissie Transplant Infectious Disease 15 (4), 354-360, 2013 | 14 | 2013 |
Shebli Atrash, MD, MS, FACPLevine Cancer Institute / Atrium Health在 carolinashealthcare.org 的电子邮件经过验证
